CYCC Historical Earnings image   This CYCC historical earnings page last updated 8/19/2022
CYCC Historical Revenue
PeriodHistorical Earnings DateGAAP
Q2 20228/10/2022NA
Q1 20225/11/2022NA
Q4 20213/28/2022NA
Q3 202111/10/2021NA
Q2 20218/11/2021NA
Q1 20215/12/2021NA
Q4 20202/25/2021NA
Q3 202011/11/2020NA
Q2 20208/12/2020NA
Q1 20205/12/2020NA
Q4 20192/26/2020NA
Q3 201911/13/2019NA
Q2 20198/13/2019NA
Q1 20195/14/2019NA
Q4 20183/27/2019150000
Q3 201811/12/2018NA
Q2 20188/9/2018NA
Q1 20185/14/2018NA
Q4 20173/28/2018NA
Q3 201711/9/2017NA
Q2 20178/9/2017NA
Q1 20175/11/2017NA
Q4 20163/28/2017277000
Q3 201611/14/2016205000
Q2 20168/10/2016222000
Q1 20165/11/2016139000
Q4 20153/24/2016424000
Q3 201511/12/2015715000
Q2 20158/11/2015296000
Q1 20155/12/2015512000
Q4 20143/24/2015247000
Q3 201411/11/2014735000
Q2 20148/12/2014264000
Q1 20145/13/2014396000
Q4 20133/25/2014299000
Q3 201311/12/201338000
Q2 20138/14/201326000
Q1 20135/13/2013NA
Q4 20123/27/2013NA
CYCC Historical Earnings EPS
PeriodHistorical Earnings DateGAAP
Q2 20228/10/2022-0.460
Q1 20225/11/2022-0.420
Q4 20213/28/2022-0.540
Q3 202111/10/2021-0.540
Q2 20218/11/2021-0.560
Q1 20215/12/2021-0.500
Q4 20202/25/2021-1.340
Q3 202011/11/2020-0.470
Q2 20208/12/2020-0.580
Q1 20205/12/2020-1.480
Q4 20192/26/2020-2.800
Q3 201911/13/2019-2.200
Q2 20198/13/2019-2.200
Q1 20195/14/2019-2.800
Q4 20183/27/2019-3.400
Q3 201811/12/2018-3.600
Q2 20188/9/2018-3.200
Q1 20185/14/2018-2.400
Q4 20173/28/20182.200
Q3 201711/9/2017-3.800
Q2 20178/9/2017-10.000
Q1 20175/11/2017-7.600
Q4 20163/28/2017-13.800
Q3 201611/14/2016-17.200
Q2 20168/10/2016-20.200
Q1 20165/11/2016-21.600
Q4 20153/24/2016-24.000
Q3 201511/12/2015-19.200
Q2 20158/11/2015-24.000
Q1 20155/12/2015-45.600
Q4 20143/24/2015-50.400
Q3 201411/11/2014-52.800
Q2 20148/12/2014-52.800
Q1 20145/13/2014-60.000
Q4 20133/25/2014-45.600
Q3 201311/12/2013-76.800
Q2 20138/14/201324.000
Q1 20135/13/2013-283.200
Q4 20123/27/2013-141.600
Quotes delayed 20 minutes

Email EnvelopeFree CYCC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Cyclacel Pharmaceuticals (CYCC) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

CYCN Historical Earnings
CYH Historical Earnings
CYT Historical Earnings
CYTH Historical Earnings
CYTK Historical Earnings
DARE Historical Earnings
DAWN Historical Earnings
DBTX Historical Earnings
DCPH Historical Earnings
DCTH Historical Earnings
What was the record high CYCC historical earnings result?
In terms of earnings or revenue, what is the best CYCC historical earnings result that Cyclacel Pharmaceuticals has ever posted, and when?

✔️Accepted answer: Within our data set, the highest CYCC historical earnings result was set in Q2 2013, when Cyclacel Pharmaceuticals posted results of 24.000/share. The most successful revenue quarter within our data set was Q3 2014 when Cyclacel Pharmaceuticals reported revenue of 735000.

What was the lowest Cyclacel Pharmaceuticals historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest CYCC has reported, and when?

✔️Accepted answer: Within our data set, the lowest CYCC historical earnings result was set in Q1 2013, when Cyclacel Pharmaceuticals posted results of -283.200/share. The smallest revenue quarter within our data set was Q2 2022 when Cyclacel Pharmaceuticals reported revenue of NA.

On this page we presented the CYCC historical earnings date information for Cyclacel Pharmaceuticals. Reviewing that CYCC Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q2 2013, when CYCC posted gaap of 24.000/share. Meanwhile the lowest CYCC historical earnings result was in Q1 2013, when CYCC posted gaap of -283.200/share. Moving to Cyclacel Pharmaceuticalss historical revenue numbers, the largest revenue quarter in our data set was seen in Q3 2014 when CYCC reported 735000 in revenue, while the smallest revenue quarter was Q2 2022 when CYCC reported NA in revenue.

For self directed investors doing their due diligence on CYCC or any other given stock, their research can benefit from looking into all of the Cyclacel Pharmaceuticals historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you HistoricalEarnings.com to make it more convenient for investors to look into Cyclacel Pharmaceuticals historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for CYCC. Thanks for visiting, and the next time you need to research CYCC historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

Recommended: IACB Options Chain, Top Ten Hedge Funds Holding DIVC, KSS Options Chain.

 

CYCC Historical Earnings | www.HistoricalEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.